0.69
+9.15%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Standard BioTools
From its filings with the US Securities and Exchange Commission
Standard BioTools is based in Boston, Massachusetts and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker LAB. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $85.3m and a net loss of $74.9m. At that date it held total assets of $567.8m and shareholders' equity of $424.3m.
At Standard BioTools, Inc. ("Standard BioTools" or the "Company"), we are committed to setting the new standard in the life science tools industry through strategic consolidation, best-in-class operations and a world class management team. Our established portfolio includes essential, standardized next-generation solutions designed to help biomedical researchers develop better therapeutics faster. We offer a diverse range of instrumentation, consumables, and services that generate high-quality data across early discovery, translational and clinical research. With advanced technologies in proteomics and genomics, we empower scientists to gain deeper biological insights, accelerate discoveries, and drive improved health outcomes across diverse therapeutic areas including immunology, oncology, neuroscience, cardiometabolic diseases and more.
On June 22, 2025, we entered into a Stock Purchase Agreement (the “Purchase Agreement”) with Illumina. Pursuant to the terms of the Purchase Agreement, Illumina acquired all of the equity interests of SomaLogic, Inc. (“SomaLogic”), Sengenics Corporation LLC (“Sengenics LLC”) and Sengenics Corporation Pte Ltd (“Sengenics Pte” and together with Sengenics LLC, “Sengenics”) (collectively, the “Disposed Entities”), each a wholly owned subsidiary of the Company that operated the Company's aptamer-based and functional proteomics business, including KREX, Single SOMAmer, translational and diagnostic assays (collectively, the “SomaScan Business”) (such transaction, the “Transaction”).
Quoted from its 10-K, filed 16 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Life Sciences Tools & Services
- Listed since
- 10 Feb 2011
- Employees
- 389
- Website
- fluidigm.com ↗
- Head office
- 50 MILK STREET, BOSTON, MA, 02109
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Accelerated filer
Leadership
Pay as last reported
- Mr. Thomas CareyIndependent Chairman of the Board$335,087
- Dr. Michael EgholmPresident, Chief Executive Officer, Director, since 2022$8.3m
- Mr. Hanjoon KimChief Financial Officer$3.1m
- Mr. Sean MackayChief Business Officer$3.2m
- Mr. Eli CasdinIndependent Director$237,087
- Mr. Troy CoxIndependent Director$242,087
- Mr. Fenel EloiIndependent Director$242,087
- Ms. Kathy HibbsIndependent Director$242,087
- Dr. Franklin WitneyIndependent Director$250,087
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 36
- Environment
- 19
- Social
- 68
- Governance
- 21
- Women in the workforce
- 46%
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Innovative Products: Fluidigm Corp is known for its advanced and cutting-edge technologies that enable the analysis of individual cells, empowering researchers with high-throughput and single-cell analysis capabilities.
- Strong Intellectual Property (IP) Portfolio: The company possesses a significant number of patents and intellectual property rights, providing a competitive advantage and protection against potential imitators in the market.
- Market Leadership: Fluidigm Corp holds a prominent position in the life sciences industry, with a strong brand reputation and a wide customer base that includes leading academic institutions, biotechnology companies, and pharmaceutical organizations.
Weaknesses
- Reliance on Research Funding: The company heavily depends on government grants and research funding, which can be unpredictable and subject to budget constraints, potentially impacting their financial stability.
- High Research and Development (R&D) Costs: Developing and commercializing highly innovative products require substantial investments in R&D, which puts pressure on the company's financial resources and profitability.
- Market Volatility: The life sciences industry is highly competitive and subject to rapid technological advancements. Fluidigm Corp needs to continuously adapt to changing market dynamics and customer preferences to maintain its competitive edge.
Opportunities
- Growing Demand for Single-Cell Analysis: With the increasing interest in personalized medicine and advancements in genomics research, there is a significant opportunity for Fluidigm Corp to capture market share by providing solutions for high-throughput single-cell analysis.
- Expansion into New Geographical Markets: The company can explore untapped international markets, especially in regions with a rising focus on life sciences research, such as Asia-Pacific. Expanding the customer base beyond traditional markets would help drive revenue growth.
- Collaboration and Partnerships: Fluidigm Corp can seek strategic collaborations and partnerships with key players in the industry to leverage complementary expertise, access new technologies, and tap into untapped market segments.
Threats
- Competitive Landscape: The life sciences industry is highly competitive, with several established players and emerging startups continuously introducing new products and technologies. Fluidigm Corp needs to stay vigilant to avoid losing market share.
- Regulatory and Compliance Challenges: Changes in regulatory requirements and compliance standards can pose challenges for Fluidigm Corp, requiring additional investments and potentially delaying product launches.
- Economic Uncertainty: Economic downturns or fluctuations can impact research budgets, potentially leading to reduced spending on innovative technologies offered by Fluidigm Corp.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.